The role of asymmetric dimethylarginine and arginine in the failing heart and its vasculature

Marlieke Visser, Walter J. Paulus, Mechteld A. R. Vermeulen, Milan C. Richir, Mariska Davids, Willem Wisselink, Bas A. J. M. de Mol, Paul A. M. van Leeuwen

Research output: Contribution to journalReview articleAcademicpeer-review

55 Citations (Scopus)


Nitric oxide (NO) is formed from arginine by the enzyme nitric oxide synthase (NOS). Asymmetric dimethylarginine (ADMA) can inhibit NO production by competing with arginine for NOS binding. Therefore, the net amount of NO might be indicated by the arginine/ADMA ratio. In turn, arginine can be metabolized by the enzyme arginase, and ADMA by the enzyme dimethylarginine dimethylaminohydrolase (DDAH). While ADMA has been implicated as a cardiovascular risk factor, arginine supplementation has been indicated as a treatment in cardiac diseases. This review discusses the roles of ADMA and arginine in the failing heart and its vasculature. Furthermore, it proposes nutritional therapies to improve NO availability
Original languageEnglish
Pages (from-to)1274-1281
JournalEuropean journal of heart failure
Issue number12
Publication statusPublished - 2010

Cite this